{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:59:03Z","timestamp":1790161143412,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19ck0106368"],"award-info":[{"award-number":["JP19ck0106368"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP18K06979"],"award-info":[{"award-number":["JP18K06979"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP21K06863"],"award-info":[{"award-number":["JP21K06863"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>BRCA1-associated protein 1 (BAP1) is frequently inactivated in pleural mesothelioma and functions as a tumor suppressor through its deubiquitinating activity. In this study, we investigated the context-dependent interplay between BAP1 and ubiquitin-specific protease 1 (USP1) in mesothelioma cells, focusing on their roles in regulating FANCD2, cell proliferation, and DNA damage responses. Genetic suppression of USP1 selectively inhibited cell proliferation in BAP1-deficient mesothelioma cells, whereas reintroduction of wild-type BAP1 rescued this growth defect; notably, a catalytically inactive BAP1 mutant failed to do so, indicating that BAP1 deubiquitinase activity is required for this compensation. In contrast, depletion of FANCD2 suppressed cell proliferation irrespective of BAP1 status, underscoring the essential role of FANCD2 in mesothelioma cell survival. Although both BAP1 and USP1 were capable of deubiquitinating FANCD2 in vitro, USP1 suppression in mesothelioma cells did not provide clear biochemical evidence of altered FANCD2 ubiquitination. Instead, USP1 knockdown was associated with reduced FANCD2 transcript and protein levels, without markedly affecting FANCD2 mRNA stability. At the cellular level, USP1 depletion impaired FANCD2 focus formation and reduced its colocalization with \u03b3-H2AX in BAP1-deficient cells, consistent with defective DNA damage signaling. Despite these changes, homologous recombination (HR) efficiency was largely preserved, whereas non-homologous end joining activity was modestly increased upon USP1 suppression. Consistent with these in vitro findings, USP1 knockdown suppressed tumor growth in an intrathoracic xenograft model. Collectively, our results indicate that BAP1 and USP1 appear to regulate FANCD2 through distinct, context-dependent mechanisms, with USP1 primarily influencing FANCD2 expression and BAP1 modulating FANCD2 function at the post-translational level. Together, these findings identify USP1 as a context-dependent therapeutic vulnerability in BAP1-deficient mesothelioma and support a working model in which USP1-dependent maintenance of FANCD2 function becomes critical in the absence of functional BAP1.<\/jats:p>","DOI":"10.1038\/s41419-026-08818-7","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T17:05:39Z","timestamp":1777741539000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["BAP1 and USP1 cooperate to regulate FANCD2 stability and cell proliferation in mesothelioma cells"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5284-7957","authenticated-orcid":false,"given":"Koya","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4456-7186","authenticated-orcid":false,"given":"Shinichi","family":"Kiyonari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7057-3048","authenticated-orcid":false,"given":"Jo","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2013-2408","authenticated-orcid":false,"given":"Miki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8713-0163","authenticated-orcid":false,"given":"Yuna","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3266-6103","authenticated-orcid":false,"given":"Miki","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0258-2212","authenticated-orcid":false,"given":"Anna","family":"Ogiso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3279-6149","authenticated-orcid":false,"given":"Tomohiro","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9538-8559","authenticated-orcid":false,"given":"Tohru","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4294-8030","authenticated-orcid":false,"given":"Takashi","family":"Miida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3746-3191","authenticated-orcid":false,"given":"Yutaka","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kadomatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8485-8316","authenticated-orcid":false,"given":"Mamoru","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4752-9262","authenticated-orcid":false,"given":"Koji","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2428-3848","authenticated-orcid":false,"given":"Yoshitaka","family":"Sekido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6347-1630","authenticated-orcid":false,"given":"Yuko","family":"Murakami-Tonami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"8818_CR1","doi-asserted-by":"publisher","first-page":"230175","DOI":"10.1183\/20734735.0175-2023","volume":"20","author":"MDJ Neilly","year":"2024","unstructured":"Neilly MDJ, Pearson J, Thu AW, MacRae C, Blyth KG. Contemporary management of mesothelioma. Breathe. 2024;20:230175.","journal-title":"Breathe"},{"key":"8818_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41572-025-00640-3","volume":"11","author":"DA Fennell","year":"2025","unstructured":"Fennell DA, Sekido Y, Baas P, Husain AN, Curioni-Fontecedro A, Lim E, et al. Pleural mesothelioma. Nat Rev Dis Prim. 2025;11:56.","journal-title":"Nat Rev Dis Prim"},{"key":"8818_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48:407\u201316.","journal-title":"Nat Genet"},{"key":"8818_CR4","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","volume":"127","author":"S Hiltbrunner","year":"2022","unstructured":"Hiltbrunner S, Fleischmann Z, Sokol ES, Zoche M, Felley-Bosco E, Curioni-Fontecedro A. Genomic landscape of pleural and peritoneal mesothelioma tumours. Br J Cancer. 2022;127:1997\u20132005.","journal-title":"Br J Cancer"},{"key":"8818_CR5","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng.855","volume":"43","author":"M Bott","year":"2011","unstructured":"Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43:668\u201372.","journal-title":"Nat Genet"},{"key":"8818_CR6","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41418-020-00709-4","volume":"28","author":"L Masclef","year":"2021","unstructured":"Masclef L, Ahmed O, Estavoyer B, Larriv\u00e9e B, Labrecque N, Nijnik A, et al. Roles and mechanisms of BAP1 deubiquitinase in tumor suppression. Cell Death Differ. 2021;28:606\u201325.","journal-title":"Cell Death Differ"},{"key":"8818_CR7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/cge.12630","volume":"89","author":"K Rai","year":"2016","unstructured":"Rai K, Pilarski R, Cebulla CM, Abdel-Rahman MH. Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet. 2016;89:285\u201394.","journal-title":"Clin Genet"},{"key":"8818_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc3459","volume":"13","author":"M Carbone","year":"2013","unstructured":"Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G. BAP1 and cancer. Nat Rev Cancer. 2013;13:153\u20139.","journal-title":"Nat Rev Cancer"},{"key":"8818_CR9","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","volume":"43","author":"JR Testa","year":"2011","unstructured":"Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43:1022\u20135.","journal-title":"Nat Genet"},{"key":"8818_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-cancerbio-030617-050422","volume":"3","author":"J Niraj","year":"2019","unstructured":"Niraj J, F\u00e4rkkil\u00e4 A, D\u2019Andrea AD. The Fanconi anemia pathway in cancer. Annu Rev Cancer Biol. 2019;3:457\u201378.","journal-title":"Annu Rev Cancer Biol"},{"key":"8818_CR11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.molcel.2016.11.005","volume":"65","author":"S Van Twest","year":"2017","unstructured":"Van Twest S, Murphy VJ, Hodson C, Tan W, Swuec P, O\u2019Rourke JJ, et al. Mechanism of ubiquitination and deubiquitination in the Fanconi anemia pathway. Mol Cell. 2017;65:247\u201359.","journal-title":"Mol Cell"},{"key":"8818_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10408-5","volume":"10","author":"F Liang","year":"2019","unstructured":"Liang F, Miller AS, Longerich S, Tang C, Maranon D, Williamson EA, et al. DNA requirement in FANCD2 deubiquitination by USP1-UAF1-RAD51AP1 in the Fanconi anemia DNA damage response. Nat Commun. 2019;10:2849.","journal-title":"Nat Commun"},{"key":"8818_CR13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.molcel.2005.01.008","volume":"17","author":"SMB Nijman","year":"2005","unstructured":"Nijman SMB, Huang TT, Dirac AMG, Brummelkamp TR, Kerkhoven RM, D\u2019Andrea AD, et al. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell. 2005;17:331\u20139.","journal-title":"Mol Cell"},{"key":"8818_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61768-0","volume":"16","author":"N Keijzer","year":"2025","unstructured":"Keijzer N, Sakoltchik J, Majumder K, Van Lil N, El Oualid F, Fish A, et al. USP1\/UAF1 targets polyubiquitinated PCNA with an exo-cleavage mechanism that can temporarily enrich for monoubiquitinated PCNA. Nat Commun. 2025;16:6991.","journal-title":"Nat Commun"},{"key":"8818_CR15","doi-asserted-by":"publisher","first-page":"103807","DOI":"10.1016\/j.dnarep.2025.103807","volume":"146","author":"AM Mazloumi Aboukheili","year":"2025","unstructured":"Mazloumi Aboukheili AM, Walden H. USP1 in regulation of DNA repair pathways. DNA Repair. 2025;146:103807.","journal-title":"DNA Repair"},{"key":"8818_CR16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/ncb1378","volume":"8","author":"TT Huang","year":"2006","unstructured":"Huang TT, Nijman SMB, Mirchandani KD, Galardy PJ, Cohn MA, Haas W, et al. Regulation of monoubiquitinated PCNA by DUB autocleavage. Nat Cell Biol. 2006;8:341\u20137.","journal-title":"Nat Cell Biol"},{"key":"8818_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03896-w","volume":"20","author":"C Fang","year":"2025","unstructured":"Fang C, Zhu Z, Cao J, Huang J, Xu Y. Comprehensive review on Fanconi anemia: insights into DNA interstrand cross-links, repair pathways, and associated tumors. Orphanet J Rare Dis. 2025;20:389.","journal-title":"Orphanet J Rare Dis"},{"key":"8818_CR18","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/s41571-018-0055-6","volume":"15","author":"A Ashworth","year":"2018","unstructured":"Ashworth A, Lord CJ. Synthetic lethal therapies for cancer: what\u2019s next after PARP inhibitors? Nat Rev Clin Oncol. 2018;15:564\u201376.","journal-title":"Nat Rev Clin Oncol"},{"key":"8818_CR19","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.4161\/cc.27983","volume":"13","author":"Y Murakami-Tonami","year":"2014","unstructured":"Murakami-Tonami Y, Kishida S, Takeuchi I, Katou Y, Maris JM, Ichikawa H, et al. Inactivation of SMC2 shows a synergistic lethal response in MYCN -amplified neuroblastoma cells. Cell Cycle. 2014;13:1115\u201331.","journal-title":"Cell Cycle"},{"key":"8818_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/srep31615","volume":"6","author":"Y Murakami-Tonami","year":"2016","unstructured":"Murakami-Tonami Y, Ikeda H, Yamagishi R, Inayoshi M, Inagaki S, Kishida S, et al. SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells. Sci Rep. 2016;6:31615.","journal-title":"Sci Rep"},{"key":"8818_CR21","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","volume":"37","author":"DA Fennell","year":"2019","unstructured":"Fennell DA, Baas P, Taylor P, Nowak AK, Gilligan D, Nakano T, et al. Maintenance defactinib versus placebo after first-line chemotherapy in patients with merlin-stratified pleural mesothelioma: COMMAND\u2014a double-blind, randomized, phase II study. J Clin Oncol. 2019;37:790\u20138.","journal-title":"J Clin Oncol"},{"key":"8818_CR22","doi-asserted-by":"publisher","unstructured":"Shapiro IM, Kolev VN, Vidal CM, Kadariya Y, Ring JE, Wright Q, et al. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med [Internet]. 2014 [cited 2025 Sep 12];6. Available from: https:\/\/doi.org\/10.1126\/scitranslmed.3008639.","DOI":"10.1126\/scitranslmed.3008639"},{"key":"8818_CR23","doi-asserted-by":"publisher","first-page":"5960","DOI":"10.1038\/sj.onc.1209587","volume":"25","author":"PI Poulikakos","year":"2006","unstructured":"Poulikakos PI, Xiao GH, Gallagher R, Jablonski S, Jhanwar SC, Testa JR. Re-expression of the tumor suppressor NF2\/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene. 2006;25:5960\u20138.","journal-title":"Oncogene"},{"key":"8818_CR24","doi-asserted-by":"publisher","first-page":"13757","DOI":"10.18632\/oncotarget.3765","volume":"6","author":"JJ Sacco","year":"2015","unstructured":"Sacco JJ, Kenyani J, Butt Z, Carter R, Chew HY, Cheeseman LP, et al. Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors. Oncotarget. 2015;6:13757\u201371.","journal-title":"Oncotarget"},{"key":"8818_CR25","doi-asserted-by":"publisher","first-page":"102091","DOI":"10.1016\/j.ctrv.2020.102091","volume":"90","author":"BH Louie","year":"2020","unstructured":"Louie BH, Kurzrock R. BAP1: Not just a BRCA1-associated protein. Cancer Treat Rev. 2020;90:102091.","journal-title":"Cancer Treat Rev"},{"key":"8818_CR26","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41420-022-01232-w","volume":"8","author":"K Suzuki","year":"2022","unstructured":"Suzuki K, Tange M, Yamagishi R, Hanada H, Mukai S, Sato T, et al. SMG6 regulates DNA damage and cell survival in Hippo pathway kinase LATS2-inactivated malignant mesothelioma. Cell Death Discov. 2022;8:446.","journal-title":"Cell Death Discov"},{"key":"8818_CR27","doi-asserted-by":"publisher","first-page":"108865","DOI":"10.1016\/j.pharmthera.2025.108865","volume":"271","author":"C Torrado","year":"2025","unstructured":"Torrado C, Ashton NW, D\u2019Andrea AD, Yap TA. USP1 inhibition: a journey from target discovery to clinical translation. Pharm Ther. 2025;271:108865.","journal-title":"Pharm Ther"},{"key":"8818_CR28","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1182\/blood-2001-12-0207","volume":"100","author":"M Ito","year":"2002","unstructured":"Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, et al. NOD\/SCID\/\u03b3cnull mouse: an excellent recipient mouse model for engraftment of human cells. Blood. 2002;100:3175\u201382.","journal-title":"Blood"},{"key":"8818_CR29","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1349-7006.2006.00184.x","volume":"97","author":"N Usami","year":"2006","unstructured":"Usami N, Fukui T, Kondo M, Taniguchi T, Yokoyama T, Mori S, et al. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci. 2006;97:387\u201394.","journal-title":"Cancer Sci"},{"key":"8818_CR30","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/cas.12698","volume":"106","author":"S Hakiri","year":"2015","unstructured":"Hakiri S, Osada H, Ishiguro F, Murakami H, Murakami-Tonami Y, Yokoi K, et al. Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells. Cancer Sci. 2015;106:990\u20139.","journal-title":"Cancer Sci"},{"key":"8818_CR31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1158\/0008-5472.CAN-08-3355","volume":"69","author":"H Nishikawa","year":"2009","unstructured":"Nishikawa H, Wu W, Koike A, Kojima R, Gomi H, Fukuda M, et al. BRCA1-associated protein 1 interferes with BRCA1\/BARD1 RING heterodimer activity. Cancer Res. 2009;69:111\u20139.","journal-title":"Cancer Res"},{"key":"8818_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05085-9","volume":"9","author":"S Asada","year":"2018","unstructured":"Asada S, Goyama S, Inoue D, Shikata S, Takeda R, Fukushima T, et al. Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis. Nat Commun. 2018;9:2733.","journal-title":"Nat Commun"},{"key":"8818_CR33","doi-asserted-by":"publisher","first-page":"34179","DOI":"10.1074\/jbc.M109.046755","volume":"284","author":"YJ Machida","year":"2009","unstructured":"Machida YJ, Machida Y, Vashisht AA, Wohlschlegel JA, Dutta A. The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. J Biol Chem. 2009;284:34179\u201388.","journal-title":"J Biol Chem"},{"key":"8818_CR34","doi-asserted-by":"publisher","first-page":"981701","DOI":"10.3389\/ftox.2022.981701","volume":"4","author":"EM Longhin","year":"2022","unstructured":"Longhin EM, El Yamani N, Rund\u00e9n-Pran E, Dusinska M. The alamar blue assay in the context of safety testing of nanomaterials. Front Toxicol. 2022;4:981701.","journal-title":"Front Toxicol"},{"key":"8818_CR35","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/cbic.201100706","volume":"13","author":"PP Geurink","year":"2012","unstructured":"Geurink PP, El Oualid F, Jonker A, Hameed DS, Ovaa H. A general chemical ligation approach towards isopeptide-linked ubiquitin and ubiquitin-like assay reagents. ChemBioChem. 2012;13:293\u20137.","journal-title":"ChemBioChem"},{"key":"8818_CR36","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","volume":"45","author":"JN Weinstein","year":"2013","unstructured":"The Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, Mills GB, Shaw KRM, Ozenberger BA, et al. The cancer genome atlas pan-cancer analysis project. Nat Genet. 2013;45:1113\u201320.","journal-title":"Nat Genet"},{"key":"8818_CR37","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"8818_CR38","doi-asserted-by":"publisher","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal [Internet]. 2013 [cited 2026 Feb 9];6. Available from: https:\/\/doi.org\/10.1126\/scisignal.2004088.","DOI":"10.1126\/scisignal.2004088"},{"key":"8818_CR39","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/ng.2653","volume":"45","author":"J Lonsdale","year":"2013","unstructured":"Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, et al. The genotype-tissue expression (GTEx) project. Nat Genet. 2013;45:580\u20135.","journal-title":"Nat Genet"},{"key":"8818_CR40","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1101\/gad.13.20.2633","volume":"13","author":"AJ Pierce","year":"1999","unstructured":"Pierce AJ, Johnson RD, Thompson LH, Jasin M. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev. 1999;13:2633\u20138.","journal-title":"Genes Dev"},{"key":"8818_CR41","doi-asserted-by":"publisher","first-page":"e28756","DOI":"10.1371\/journal.pone.0028756","volume":"6","author":"H Ogiwara","year":"2011","unstructured":"Ogiwara H, Kohno T. Essential factors for incompatible DNA end joining at chromosomal DNA double strand breaks in vivo. PLoS ONE. 2011;6:e28756.","journal-title":"PLoS ONE"},{"key":"8818_CR42","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1038\/onc.2010.592","volume":"30","author":"H Ogiwara","year":"2011","unstructured":"Ogiwara H, Ui A, Otsuka A, Satoh H, Yokomi I, Nakajima S, et al. Histone acetylation by CBP and p300 at double-strand break sites facilitates SWI\/SNF chromatin remodeling and the recruitment of non-homologous end joining factors. Oncogene. 2011;30:2135\u201346.","journal-title":"Oncogene"},{"key":"8818_CR43","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1038\/s41388-018-0417-7","volume":"38","author":"A Matsushita","year":"2019","unstructured":"Matsushita A, Sato T, Mukai S, Fujishita T, Mishiro-Sato E, Okuda M, et al. TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation. Oncogene. 2019;38:1966\u201378.","journal-title":"Oncogene"},{"key":"8818_CR44","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nchembio.1455","volume":"10","author":"Q Liang","year":"2014","unstructured":"Liang Q, Dexheimer TS, Zhang P, Rosenthal AS, Villamil MA, You C, et al. A selective USP1\u2013UAF1 inhibitor links deubiquitination to DNA damage responses. Nat Chem Biol. 2014;10:298\u2013304.","journal-title":"Nat Chem Biol"},{"key":"8818_CR45","doi-asserted-by":"publisher","first-page":"8099","DOI":"10.1021\/jm5010495","volume":"57","author":"TS Dexheimer","year":"2014","unstructured":"Dexheimer TS, Rosenthal AS, Luci DK, Liang Q, Villamil MA, Chen J, et al. Synthesis and structure\u2013activity relationship studies of N -benzyl-2-phenylpyrimidin-4-amine derivatives as potent USP1\/UAF1 deubiquitinase inhibitors with anticancer activity against nonsmall cell lung cancer. J Med Chem. 2014;57:8099\u2013110.","journal-title":"J Med Chem"},{"key":"8818_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-12-91","volume":"12","author":"I Garc\u00eda-Santisteban","year":"2013","unstructured":"Garc\u00eda-Santisteban I, Peters GJ, Giovannetti E, Rodr\u00edguez JA. USP1 deubiquitinase: cellular functions, regulatory mechanisms and emerging potential as target in cancer therapy. Mol Cancer. 2013;12:91.","journal-title":"Mol Cancer"},{"key":"8818_CR47","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41594-021-00576-8","volume":"28","author":"ML Rennie","year":"2021","unstructured":"Rennie ML, Arkinson C, Chaugule VK, Toth R, Walden H. Structural basis of FANCD2 deubiquitination by USP1\u2009\u2212\u2009UAF1. Nat Struct Mol Biol. 2021;28:356\u201364.","journal-title":"Nat Struct Mol Biol"},{"key":"8818_CR48","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/sj.onc.1201861","volume":"16","author":"DE Jensen","year":"1998","unstructured":"Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA, et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene. 1998;16:1097\u2013112.","journal-title":"Oncogene"},{"key":"8818_CR49","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jtho.2017.03.023","volume":"12","author":"R Parrotta","year":"2017","unstructured":"Parrotta R, Okonska A, Ronner M, Weder W, Stahel R, Penengo L, et al. A novel BRCA1-associated protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair. J Thorac Oncol. 2017;12:1309\u201319.","journal-title":"J Thorac Oncol"},{"key":"8818_CR50","first-page":"593","volume":"9","author":"DA Fennell","year":"2021","unstructured":"Fennell DA, King A, Mohammed S, Branson A, Brookes C, Darlison L, et al. Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial. Lancet. Respir Med. 2021;9:593\u2013600.","journal-title":"Respir Med"},{"key":"8818_CR51","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jtho.2020.01.012","volume":"15","author":"D Rathkey","year":"2020","unstructured":"Rathkey D, Khanal M, Murai J, Zhang J, Sengupta M, Jiang Q, et al. Sensitivity of mesothelioma cells to PARP inhibitors is not dependent on BAP1 but is enhanced by temozolomide in cells with high-schlafen 11 and low-O6-methylguanine-DNA methyltransferase expression. J Thorac Oncol. 2020;15:843\u201359.","journal-title":"J Thorac Oncol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08818-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08818-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08818-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:03:46Z","timestamp":1781845426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08818-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8818"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08818-7","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"583"}}